CD274 and neoplasm: Preclinical in vitro and in vivo experiments have shown that PD-1 and/or PD-L1 blockade using monoclonal antibodies enhances tumor cell-specific T-cell activation, cytokine production, anti-tumor effector mechanisms, and the clearance of tumor cells by the immune system [12–16].